No Data
There is a significant discrepancy between domestic and foreign investors regarding Hong Kong stocks, yet southern capital is gradually increasing its investment. Who is the smartest investor?
①As the Hong Kong stock market retraces, foreign institutions are gradually selling some Hong Kong stocks to stop losses; ②Southbound funds are buying on dips, with the purchase scale in November hitting a new high in almost three years; ③Foreign institutions are flowing out of Hong Kong stocks and other emerging markets under risk aversion demand.
Hong Kong stock market midday review | The three major indexes rebounded after testing the lows, with the Hang Seng Index rising by 0.36%; biomedical stocks were strong, with Global New Materials up over 11% and wuxi apptec up over 5%.
Network technology stocks showed mixed performance, with Bilibili-W up 2.39% and Meituan-W down 2.33%; semiconductor stocks generally fell, with Ingdan dropping 3.70% and Solomon Systech down 2.04%; electrical utilities stocks strengthened, with CGN Power up 3.09% and CKI Holdings up 3.08%.
Market movements | Bullish market stimuli lift Hong Kong pharmaceutical stocks, with Genscript soaring more than 12% and wuxi bio rising nearly 5%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
Hong Kong stocks movement | trad chi med (00570) continues to decline after privatization failure, rebounding over 8% in the morning, institutions say the logic of state-owned enterprise reform continues to unfold.
Trad chi med (00570) has been continuously declining after privatization. It rebounded by over 8% in early trading today, up 7.66% as of the time of publication, at 2.39 Hong Kong dollars, with a turnover of 0.218 billion Hong Kong dollars.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
The National Medical Insurance Administration: Negotiated pharmaceuticals during the agreement period have reduced the financial burden on patients by over 880 billion yuan.
This morning, the National Medical Insurance Administration announced the new version of the pharmaceutical catalog at a press conference. A responsible official from the National Medical Insurance Administration stated at the meeting that since its establishment, the speed of new drugs entering the catalog has continuously accelerated, allowing insured individuals to enjoy the benefits brought by pharmaceutical innovation in a timely manner. As of the end of October this year, the cumulative number of beneficiaries from negotiated pharmaceutical products during the agreement period reached 0.83 billion people, alleviating the financial burden on patients by more than 880 billion yuan. With more new drugs entering the catalog, the level of benefits for patients will steadily improve, which will effectively enhance the confidence of the pharmaceutical industry in increasing research and development innovation, conducive to better promoting economic and social development.
